

# VIF World 2024 Agenda

Day 1 Mar. 21

## Morning Plenary Session

### **0900 Plenary Panel: Next-generation vaccine technologies: innovations and challenges**

- Explore the latest advancements in vaccine technologies, such as mRNA vaccines and viral vector platforms.
- Discuss the potential impact of these innovations on global vaccine development and deployment.
- Address challenges related to safety, efficacy, and public perception of these cutting-edge vaccine modalities.

### **0945 Plenary Panel: Equitable access to vaccines: overcoming barriers and bridging Gaps**

- Examine the current state of global vaccine distribution and accessibility.
- Discuss strategies to ensure equitable access to vaccines, particularly in low-income countries.
- Explore collaborative efforts between governments, NGOs, and pharmaceutical companies to bridge gaps in vaccine availability and distribution.

Jiguo Zhang, President Fosun Vaccine

Hum Kim, President of Global Business, SK Bioscience, South Korea

Jian Dong, CEO, Wuxi Vaccines

Raman Rao, CEO, Hilleman Laboratories

Derrick Sim, Managing Director - Vaccine Markets and Health Security, GAVI

### **1030 Tea Break**

### **1100 Keynote: The transformation of vaccinology: recent achievements and future prospects**

Michel De Wilde, Former SVP, R&D, Sanofi Pasteur; Owner, MDWConsultant

### **1130 Keynote: Advancing global health through vaccines**

TBC

### **1150 Keynote: TBC**

Jicui Dong, Head, Local Production and Assistance Unit, Regulation and Prequalification Department, Access to Medicines and Health Products Division, WHO, Geneva, Switzerland

Contact us through [sam.li@chstone-events.com](mailto:sam.li@chstone-events.com) or 86-13482341046

# VIF World 2024 Agenda

1210 Keynote: TBC

1230 Networking Lunch

## Afternoon Session

Stream A COVID& Respiratory	Stream B Bioprocessing & Manufacturing	Stream C Cancer Vaccine & Immunotherapy & RNA
<p><b>1330 Next generation COVID vaccines</b> Jeffrey Ulmer, President, TechImmune, USA</p> <p><b>1355 Clinical development of ARCT-154, the first approved sa-mRNA vaccine</b> Igor Smolenov Chief Development Officer, Vaccines, Arcturus Therapeutics</p> <p><b>1425 Africa's new public health order: lessons from covid-19 pandemic</b> Nicaise Ndembi, Chief Science Advisor, Africa Centres for Disease Control and Prevention, Ethiopia</p> <p><b>1450 TBC</b></p> <p><b>1515 TBC</b> Nicholas Jackson, President of R&amp;D, Clover Biopharma</p>	<p><b>1330 Innovations in vaccine technologies: manufacturing perspective</b> Rajinder Suri, CEO, DCVMN International, Switzerland</p> <p><b>1355 Intranasal immunization: device and formulation promises and challenges</b> Reserved by Aptar</p> <p><b>1425 TBC</b></p> <p><b>1450 Innovations in end-to-end mRNA vaccine research, development and manufacturing: Progress and Partnerships of the mRNA Technology Development and Transfer programme</b> Petro Terblanche, CEO, Afrigen Biologics, South Africa</p> <p><b>1515 Cell-based vaccine production: breaking new ground (TBD)</b> Reserved by TURBOMAX</p>	<p><b>1330 Systems biology based rapid response to emerging infectious diseases -Developing immunotherapeutic interventions</b> Kar Muthumani, CSO, GeneOne Life Science, USA</p> <p><b>1400 Therapeutic DNA vaccine development (TBC)</b> David Weiner, Executive Vice President, The Wistar Institute</p> <p><b>1430 mRNA vaccines against Clostridium difficile</b> Mohamad-Gabriel Alameh, Assistant Professor, U Penn</p> <p><b>1500 TBC</b></p>
<p><b>1540 Break</b></p> <p><b>1600 A bivalent RSV mRNA vaccine developed based on</b></p>	<p><b>1530 Break</b></p> <p><b>1600 TBC</b></p>	<p><b>1530 Break</b></p> <p><b>1600 TBC</b></p>

Contact us through [sam.li@chstone-events.com](mailto:sam.li@chstone-events.com) or 86-13482341046

# VIF World 2024 Agenda

## Innorna's mRNA/LNP technology platform

Zhangjing (Jim) Chen, VP, Innorna, China

## 1625 TBC

## 1640 Using non-changeable against changeable strategy to develop pan-HCoV vaccines

Shibo Jiang, Professor, Fudan University, China

## 1705 RSV vaccine development

Bin Wang, CSO, Advaccine/Professor, Fudan University, China

## 1730 Inhaled vaccine, new platforms for respiratory infectious diseases

Tao Zhu, CSO, Cansino Biologics

## 1800 End of Day One

## 1630 Navigating the Regulatory path for micro-array patches (MAP) vaccines

Maria Dul, Research Associate, Cardiff University

## 1700 Bioprocess development for vaccines for infectious diseases

Héla KALLEL, Head of Process Development, Quantoom

## 1715 Tackling thermostability and biodegradation challenges in mRNA vaccine through rapid onsite microfluidic assembly (ROMA) technology

Jiang Xu, Senior Scientist, Virogin Biotech

## 1730 Innovating and digitalising mRNA vaccine and therapeutics production platform processes

Zoltan Kis, Lecturer, University of Sheffield, UK

## 1800 End of Day One

Ken Ishii, Director, International Vaccine Design Center, Professor, University of Tokyo, Japan

## 1630 mRNA cancer vaccine development

Hangwen Li, CEO, Stemirna

## 1700 TBC

## 1730 SynNeogen® immunotherapy platform— New strategies for clinical development of therapeutic vaccines for chronic hepatitis B and prostate cancer

Eric Yuenian Shi, CEO, Chimigen

## 1745 Clinical trial of an immunotherapy for the treatment of COVID-19

Mingi Chang, R&D Director, Advagene, China

## 1800 End of Day One

Day 2 Mar. 22

Morning Session

Contact us through [sam.li@chstone-events.com](mailto:sam.li@chstone-events.com) or 86-13482341046

# VIF World 2024 Agenda

Stream D Novel Vaccine Development	Stream E Vaccine Design& Innovation	Stream F Novel Platform &Partnership
<p><b>Chair:</b>George Siber, President, Siber Biotechnologies LLC, USA</p> <p><b>0900AMR vaccine development in China</b> Quanming Zou, Professor, Army Medical University</p> <p><b>0925 Next generation pneumococcal vaccines</b> George Siber, President, Siber Biotechnologies</p> <p><b>0950 Reserved by Wuxi Biologics</b></p> <p><b>1020 Reserved by PMF Biotech</b></p> <p><b>1040 Break</b></p> <p><b>1100 TBC</b> Shan Lu, Professor, University of Massachusetts Medical School, USA</p> <p><b>1125 Novel vaccine development through global alliance</b> Hun Kim, President of Global Business, SK Bioscience, South Korea</p>	<p><b>0900 Structure-based vaccine design for HIV (TBD)</b> Tongqing Zhou, Chief of the Structural Bioinformatics Core Section, NIAID</p> <p><b>0925 leveraging novel technology to accelerate vaccine development (TBD)</b> Linqi Zhang, Professor, Tsinghua University</p> <p><b>0950 TBC</b> Shaowei Li, Professor, Xiamen University</p> <p><b>1015 TBC</b></p> <p><b>1040 Tea break</b></p> <p><b>1100 Developing affordable vaccines for LMICs</b> Raman Rao, CEO, Hilleman Laboratories</p> <p><b>1125 Genetically engineered innovative bacterial vaccines</b> Rong Xu, CSO, Delonix Bioworks</p>	<p><b>0900 mRNA vaccine development beyond Covid-19</b> Kiat Ruxrungtham, Director of Chula VRC, Chulalongkorn University, Thailand</p> <p><b>0925 TBC</b></p> <p><b>0950 mRNA vaccine development based on a nano-drug delivery technology</b> Dal-Hee Min, CTO, Lemonex, South Korea</p> <p><b>1005 AstriVax, a novel vaccine platform committed to address real world vaccinology challenges</b> Hanne Callewaert, CEO, AstriVax</p> <p><b>1020 TBC</b></p> <p><b>1040 Tea Break</b></p> <p><b>1100 A novel mRNA vaccine for monkey pox</b> William Jia, CSO, Virogin/CNBG-Virogin</p> <p><b>TBC</b> Emanuele Montomoli, VisMederi</p> <p><b>Research and development of a novel human DNA vaccine platform</b> Xia Jin, CEO, Co-founder, Cure BioTech</p>

Contact us through [sam.li@chstone-events.com](mailto:sam.li@chstone-events.com) or 86-13482341046

# VIF World 2024 Agenda

<p><b>1150 Helicobacter pylori vaccine development</b> Fan Fan, VP, Head of Research Institute, Olymvax</p> <p><b>1205 Inactivated Rotavirus Vaccine (IRV) Development: An Update (TBC)</b> Baoming Jiang, Senior Scientist, Division of Viral Diseases-CDC, USA</p> <p><b>1230 Lunch</b></p>	<p><b>1140 Harnessing innate immunity and inflammation for enhancing vaccine efficacy</b> Diana Boraschi, Distinguished Professor, Shenzhen Institute of Advanced Technology</p> <p><b>1205 Novel vaccine development</b> Aldo Tagliabue, Chief Scientist, Shenzhen Institute of Advanced Technology</p> <p><b>1230 Lunch</b></p>	<p><b>mRNA Nano-vaccines against EBV-positive Tumors</b> Xiangrong Song, CEO, Co-founder, WestGene Biopharma</p> <p><b>Sa-mRNA based vaccine development</b> Yuanqing Liu, CSO, Immorna China</p> <p><b>1230 Lunch</b></p>
---	---	--

## Afternoon Session

Stream G Novel Vaccine Development	Stream H Adjuvant & Mucosal & Delivery	Stream I Clinical Trial, Market Access
<p><b>1330 Development of polyvalent pneumococcal conjugate vaccine against pneumococcal diseases</b> Jeff Zhu, Founder&amp;CEO, Reinovax Biologics</p> <p><b>1355 An update of vaccine development on Hepatitis E</b> James Wai Kuo Shih, Senior Advisor, Xiamen Inovax Biotech, China</p> <p><b>1420 TBC</b></p> <p><b>1445 Development of a pneumococcal conjugate vaccine and novel vaccines through research driven efforts in India</b> Ramesh Matur, Sr Vice President and Head of Vaccines R&amp;D, Biological E, India</p>	<p><b>1330 Advax-CpG Adjuvant</b> Nikolai Petrovsky, Founder, Vaxine, Australia</p> <p><b>1355 Evolution of flagellin adjuvant towards clinical application</b> Joon Haeng Rhee, Professor, Chonnam National University Medical School</p> <p><b>1420 Interferons and inflammasomes in adjuvant induced immune responses</b> Ed Lavelle, Professor, Trinity College Dublin, Ireland</p> <p><b>1445 Mucosal adjuvants</b> Elizabeth Norton, Associate Professor, Tulane University</p> <p><b>1510 TBC</b></p>	<p><b>1330 Regulatory strategy to accelerate vaccine approval (TBC)</b> Robby Hu, Associate Director, RA, MSD</p> <p><b>1400 Clinical strategy in Emerging Markets</b> Reserved by SDM CRO</p> <p><b>Evaluation on mucosal respiratory COVID -19 vaccines in clinical trials</b> Jingxin Li, Vice Director of the Department, Jiangsu CDC</p> <p><b>Randomized double blind Clinical Trial on Covid-19 vaccine</b> Muhammad Raza Shah, Professor and Director, International Center for Chemical and Biological Sciences, University of Karachi</p> <p><b>1535 Tea Break</b></p>

Contact us through [sam.li@chstone-events.com](mailto:sam.li@chstone-events.com) or 86-13482341046

# VIF World 2024 Agenda

**1510 Investigation of virus-like structure vaccine based on technological strategy of lipid delivery**  
Qihan Li, PI, Professor, IMBCAM

**1535 Tea Break**

**1555 Development of in vitro - assembled multivalent VLP vaccine for norovirus infection**  
Deog-Young Choi, CEO, InThera, South Korea

**1615 Progress toward AIDS vaccines**  
Feng Gao, Professor, Jinan University

**1635**

**1700 Development of Nanoparticle Human Vaccines Utilizing A Proprietary IC-BEVS Platform**  
Enqi Du, GM& CSO, Chengdu Microgen

**Speaking slots available**

**1800 End of Day Two**

**1535 Tea Break**

**1555 Intranasal vaccination can build effective mucosal immunity wall against Omicron infection**  
Ling Chen, PI, Guangzhou Laboratory

**1620 TBC**

**1645 TLR5 pathway-based mucosal adjuvant for design of subunit mucosal vaccines**  
Huimin Yan, Professor, Shanghai Public Health Clinical Center, Fudan University

**1710 Engineered design of mucus penetration nanoparticles for inhalable vaccines**  
Bingbing Sun, Professor, Dalian University of Technology

**1735 Innovative and High-Performing Lipids for mRNA Delivery**  
Yongming Chen, Professor, Sun Yat-sen University

**1750 TBC**

**1800 End of Day Two**

**1555 Commercial strategy for international market, a perspective from a Chinese vaccine company**  
Chongqing Zhifei Biological Products Co

**Speaking slot available**

**1800 End of Day Two**

**Day 3 Mar. 23**

**Morning Session**

Contact us through [sam.li@chstone-events.com](mailto:sam.li@chstone-events.com) or 86-13482341046

# VIF World 2024 Agenda

## Stream J Veterinary Vaccine

### 0900 Developing a 'One Health' Nipah virus vaccine to protect animal and public health

Simon Graham, Professor, The Pirbright Institute, UK

### 0925 Advancements in Veterinary Vaccine Development: Meeting the Needs of Animal Health

Mahesh Kumar, Senior Vice President, Global Biologics R&D, Zoetis, USA

### 0950 ASFV vaccine development (TBD)

TBC

### 1015 The Importance of specific antibodies in the Development of VLP based vaccines

Huichen Guo, Professor, Lanzhou Veterinary Research Institute

### 1040 Tea Break

### 1100 Application of immunotherapy in swine vaccines

Frank Chang, CSO, Reber Genetics

### 1115 mRNA based vaccine development for animal diseases

Caiyi Fei, Co-founder & VP, Therarna

### 1130 Next-Generation High-Yield Baculovirus/Insect Cell Protein Expression System—qBac® Bacmid

Xiaodong Xu, Co-founder, Shaanxi Bacmid Biotech

### 1145 TBC

Fang Lv, Associate Professor, Jiang Academy of Agricultural Sciences

### 1200 End of Day Three

Contact us through [sam.li@chstone-events.com](mailto:sam.li@chstone-events.com) or 86-13482341046